Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases
Open Access
- 21 January 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Genetics
- Vol. 17 (1), e1009113
- https://doi.org/10.1371/journal.pgen.1009113
Abstract
A Darwinian evolutionary shift occurs early in the neutral evolution of advanced colorectal carcinoma (CRC), and copy number aberrations (CNA) are essential in the transition from adenoma to carcinoma. In light of this primary evolution, we investigated the evolutionary principles of the genome that foster postoperative recurrence of CRC. CNA and neoantigens (NAG) were compared between early primary tumors with recurrence (CRCR) and early primary tumors without recurrence (precancerous and early; PCRC). We compared CNA, single nucleotide variance (SNV), RNA sequences, and T-cell receptor (TCR) repertoire between 9 primary and 10 metastatic sites from 10 CRCR cases. We found that NAG in primary sites were fewer in CRCR than in PCRC, while the arm level CNA were significantly higher in primary sites in CRCR than in PCRC. Further, a comparison of genomic aberrations of primary and metastatic conditions revealed no significant differences in CNA. The driver mutations in recurrence were the trunk of the evolutionary phylogenic tree from primary sites to recurrence sites. Notably, PD-1 and TIM3, T cell exhaustion-related molecules of the tumor immune response, were abundantly expressed in metastatic sites compared to primary sites along with the increased number of CD8 expressing cells. The postoperative recurrence-free survival period was only significantly associated with the NAG levels and TCR repertoire diversity in metastatic sites. Therefore, CNA with diminished NAG and diverse TCR repertoire in pre-metastatic sites may determine postoperative recurrence of CRC. We found that copy number aberrations (CNAs) may be the most important selective pressure promoting cancer evolution from early-to-advanced tumors in primary sites. The diminished neoantigens (NAG) in cancer cells and the diverse TCR repertoire in cytotoxic T cells were crucial for the onset of postoperative recurrence during genomic neutral evolution, along with clonal CNA and several driver SNVs from primary to recurrent sites. Therefore, cancer metastasis could be prevented by activating CTL at the premetastatic sites before priming of the metastatic process.This publication has 30 references indexed in Scilit:
- Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencingNature Genetics, 2014
- Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular DiversityCell Reports, 2014
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- An empirical Bayesian framework for somatic mutation detection from cancer genome sequencing dataNucleic Acids Research, 2013
- EXCAVATOR: detecting copy number variants from whole-exome sequencing dataGenome Biology, 2013
- Preparing Unbiased T-Cell Receptor and Antibody cDNA Libraries for the Deep Next Generation Sequencing ProfilingFrontiers in Immunology, 2013
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingThe New England Journal of Medicine, 2012
- MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to ApoptosisThe Journal of Immunology, 2011
- Distant metastasis occurs late during the genetic evolution of pancreatic cancerNature, 2010
- Allele-specific copy number analysis of tumorsProceedings of the National Academy of Sciences of the United States of America, 2010